OncoGynecologyNews.net

OncoGynecology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Farmaexplorer.it

Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free survival ( IDFS ), significantly decreasing the risk of breast c ...


Camrelizumab is a fully humanized, monoclonal antibody against PD-1. A study has assessed the efficacy and safety of Camrelizumab plus Apatinib, a tyrosine kinase inhibitor targeting VEGFR2, in patien ...


Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR)+, estrogen receptor ( ER ) / progesterone receptor (PR)- breast cancer. The functional role of androgen ...


The CDK4/6 inhibitor Palbociclib ( Ibrance ) in combination with Letrozole ( Femara ) has become a standard first-line treatment for patients with luminal metastatic breast cancer ( MBC ) ( PALOMA-1 & ...


As part of an ongoing phase Ib/II study ( NCT02501096 ) in patients with selected solid tumors, Lenvatinib [ Lenvima ] ( 20 mg PO [ per os ] QD [ once a day ] ) + Pembrolizumab [ Keytruda ] ( 200 mg I ...


In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor, + Fulvestrant ( Faslodex ) has demonstrated statistically significant improvements in pro ...


Breast cancer drugs may force some cancer cells into sleeper mode, allowing them to potentially come back to life years after initial treatment. These are the early-stage findings from researchers at ...


Abemaciclib ( Verzenios ) is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive ( HR+ ), human epidermal growth factor receptor 2-negative ( HER2- ) ...


The phase III MONALEESA-3 trial investigated Ribociclib, a cyclin-dependent kinase 4/6 ( CDK4/6 ) inhibitor, plus Fulvestrant as first-line ( 1L ) or second-line ( 2L ) treatment for postmenopausal p ...


The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one of the dual-primary endpoints of pathological complete respon ...


A study has shown that women with specific DNA characteristics in certain areas of the genome may live longer if they take Aspirin [ Acetylsalicylic acid ] before they are diagnosed with breast cancer ...


The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate ( ADC ) was evaluated in patients with HER2-positive, un ...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free ...


Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ), remains an area of high unmet need for patients progressing after greater ...


PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational status with pCR in patients with HER2-positive early breast cancer treated with ne ...